Monocentric Crossover Study to Assess the Tolerability and the Efficacy of a Mix of Probiotic Strains Doses vs Placebo in Athletes Performance This study will intend: \- To assess the tolerability and the efficacy of a food supplements into improving performance in a panel of athletes after repeated use for 4 consecutive weeks, under the normal conditions of use, compared to a placebo.
The present study aimed at assessing the tolerability and the efficacy of a food supplements probiotics-based (L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules) into improving performance in a panel of athletes after repeated use for 4 consecutive weeks, under the normal conditions of use, compared to a placebo.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
11
probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules
placebo consisted of the same capsules filled with potato starch
Centro Sportivo Parma Football
Collecchio, Parma, Italy
Evaluation of physical parameters: soreness
Change of Soreness (measured by a 5-point scale) between T1 and T2
Time frame: at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE)
Evaluation of physical parameters: fatigue
Change of Fatigue (measured by a 5-point scale) between T1 and T2
Time frame: at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE)
Evaluation of physical parameters: energy
Change of Energy (measured by a 5-point scale) between T1 and T2between T1 and T2
Time frame: at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE)
Evaluation of physical parameters:Sleep quality
Change of Sleep quality (evaluated by Sleep Quality Scale (SQS)) between T1 and T2between T1 and T2
Time frame: at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE)
Evaluation of physical parameters:Digestive symptoms
Change of the frequency of four individual digestive symptoms (abdominal pain/discomfort, bloating, flatulence/passage of gas and borborygmi/rumbling stomach) will be evaluated with five-point Likert scales that range from 0 (never) to 4 (every day of the week), between T1 and T2
Time frame: at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE)
Gut microbiota analysis ON FECAL SAMPLE by mean of 16S and metagenomic shotgun sequencing
16S and metagenomic shotgun sequencing
Time frame: at baseline (T0)
Gut microbiota analysis ON FECAL SAMPLE by mean of 16S and metagenomic shotgun sequencing
16S and metagenomic shotgun sequencing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: at T1 (12 weeks with placebo) a
Gut microbiota analysis ON FECAL SAMPLE by mean of 16S and metagenomic shotgun sequencing
16S and metagenomic shotgun sequencing
Time frame: at T1 (12 week with ACTIVE)
Microbial dysbiosis ON URINE SAMPLES by mean of liquid chromatography- surface-activated chemical-ionization-electrospray ionization (LC/SASI-MS) and tandem mass spectrometry (MS/MS)
By mean of liquid chromatography bacteria that potentially could cause dysbiosis by analyzing the profile of urine's metabolites and combining the results in the SANIST platform which predicts the intestinal dysbiosis based on the antagonist and pathogen bacteria pharmacological activity
Time frame: at baseline (T0),
Microbial dysbiosis ON URINE SAMPLES by mean of liquid chromatography- surface-activated chemical-ionization-electrospray ionization (LC/SASI-MS) and tandem mass spectrometry (MS/MS)
By mean of liquid chromatography bacteria that potentially could cause dysbiosis by analyzing the profile of urine's metabolites and combining the results in the SANIST platform which predicts the intestinal dysbiosis based on the antagonist and pathogen bacteria pharmacological activity
Time frame: at T1 (12 weeks with placebo)
Microbial dysbiosis ON URINE SAMPLES by mean of liquid chromatography- surface-activated chemical-ionization-electrospray ionization (LC/SASI-MS) and tandem mass spectrometry (MS/MS)
By mean of liquid chromatography bacteria that potentially could cause dysbiosis by analyzing the profile of urine's metabolites and combining the results in the SANIST platform which predicts the intestinal dysbiosis based on the antagonist and pathogen bacteria pharmacological activity
Time frame: T1 (12 week with ACTIVE)